DelveInsight’s “Muscle Spasticity Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Muscle Spasticity pipeline landscapes.
The report comprises Muscle Spasticity pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Muscle Spasticity therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Muscle Spasticity pipeline products.
Muscle Spasticity Overview
Spasticity is defined as “sensorimotor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex” or from an upper motor neuron lesion (UMN), presenting as intermittent or sustained involuntary activation of muscles. The region and the extent of impairment depending on the area of the brain or spinal cord that has been damaged. It can occur in the upper and/or lower limbs.
Some of the key takeaways from the Muscle Spasticity Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as GW Pharmaceuticals, Revance Therapeutics, Ipsen, etc., are developing therapies for the treatment of Muscle Spasticity.
-
Emerging therapies such as Nabiximols, DAXI, IPN10200, are expected to have a significant impact on the Muscle Spasticity market in the coming years.
Get an overview of pipeline landscape @ Muscle Spasticity Clinical Trials Analysis
Muscle Spasticity Pipeline Therapies along with Key Players:
-
Nabiximols: GW Pharmaceuticals
-
DAXI: Revance Therapeutics
-
IPN10200: Ipsen
Scope of Muscle Spasticity Pipeline Drug Insight
-
Coverage: Global
-
Major Players: GW Pharmaceuticals, Revance Therapeutics, Ipsen, and others.
-
Pipeline Therapies: Nabiximols, DAXI, IPN10200, and others.
Table of Contents
|
1 |
Muscle Spasticity Report Introduction |
|
2 |
Muscle Spasticity Executive Summary |
|
3 |
Muscle Spasticity Overview |
|
4 |
Muscle Spasticity- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Muscle Spasticity Pipeline Therapeutics |
|
6 |
Muscle Spasticity Late Stage Products (Phase II/III) |
|
7 |
Muscle Spasticity Mid Stage Products (Phase II) |
|
8 |
Muscle Spasticity Early Stage Products (Phase I) |
|
9 |
Muscle Spasticity Preclinical Stage Products |
|
10 |
Muscle Spasticity Therapeutics Assessment |
|
11 |
Muscle Spasticity Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Muscle Spasticity Key Companies |
|
14 |
Muscle Spasticity Key Products |
|
15 |
Muscle Spasticity Unmet Needs |
|
16 |
Muscle Spasticity Market Drivers and Barriers |
|
17 |
Muscle Spasticity Future Perspectives and Conclusion |
|
18 |
Muscle Spasticity Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Muscle Spasticity Drugs Pipeline Report
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/